VYR-105

VYR-105 is a preclinical-stage therapeutic candidate being developed by Vyripharm International for the treatment of mood disorders. The drug utilizes a specialized hydrogel drug delivery system designed to optimize the release and bioavailability of its active components. While the specific active pharmaceutical ingredient (API) and molecular targets are not explicitly detailed in public pipeline summaries, the program is part of Vyripharm's broader focus on integrating advanced delivery technologies with pharmacogenomics to address psychiatric and neurological conditions. The hydrogel platform aims to provide a more controlled and effective delivery mechanism compared to traditional formulations.